Belinostat (a drug owned by Spectrum Pharmaceuticals Inc. and TopoTarget A/S).
TopoTarget posted friday that the BELIEF study have beaten the primary endpoint by the study:
https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=522265&lang=en
Their Partner, Spectrum Pharmaceuticals didnt confirm those data, and there were some misunderstandings in the market. Today, spectrum announced the following comment about the BELIEF study.
http://finance.yahoo.com/news/spectrum-pharmaceuticals-provides-belinostat-registrational-112600330.html
For me, its clear, thare there are some misunderstandings in the partnerships between Spectrum and TopoTarget.
